Skip to main content

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.

Publication ,  Journal Article
Byrd, JC; Dodge, RK; Carroll, A; Baer, MR; Edwards, C; Stamberg, J; Qumsiyeh, M; Moore, JO; Mayer, RJ; Davey, F; Schiffer, CA; Bloomfield, CD
Published in: J Clin Oncol
December 1999

PURPOSE: To examine the effect of single compared with repetitive (at least three) cycles of high-dose cytarabine after induction therapy for patients with acute myeloid leukemia (AML) who have the t(8;21)(q22;q22) karyotype. PATIENTS AND METHODS: Patients entered onto the study had AML and t(8;21) and attained a complete remission on four successive Cancer and Leukemia Group B studies. In these studies, either > or = three cycles of high-dose cytarabine or one cycle of high-dose cytarabine was administered, followed by sequential cyclophosphamide/etoposide and mitoxantrone/diaziquone with or without filgrastim support. Outcomes of these two groups of t(8;21) patients were compared. RESULTS: A total of 50 patients with centrally reviewed AML and t(8;21) were assigned to receive one (n = 29) or > or = three cycles (n = 21) of high-dose cytarabine as postinduction therapy. The clinical features of these two groups of patients were similar. Initial remission duration for t(8;21) patients assigned to one cycle of high-dose cytarabine was significantly inferior (P =.03), with 62% of patients experiencing relapse with a median failure-free survival of 10.5 months, compared with the group of patients who received > or = three cycles, in which only 19% experienced relapse and failure-free survival is estimated to be greater than 35 months. Furthermore, overall survival was also significantly compromised (P =.04) in patients assigned to one cycle of high-dose cytarabine, with 59% having died as a consequence of AML, compared with 24% of those who received > or = three cycles of high-dose cytarabine. CONCLUSION: These data demonstrate that failure-free survival and overall survival of patients with t(8;21)(q22;q22) may be compromised by treatment approaches that do not include sequential high-dose cytarabine therapy.

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

December 1999

Volume

17

Issue

12

Start / End Page

3767 / 3775

Location

United States

Related Subject Headings

  • Translocation, Genetic
  • Survival Analysis
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Humans
  • Female
  • Drug Administration Schedule
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Byrd, J. C., Dodge, R. K., Carroll, A., Baer, M. R., Edwards, C., Stamberg, J., … Bloomfield, C. D. (1999). Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol, 17(12), 3767–3775. https://doi.org/10.1200/JCO.1999.17.12.3767
Byrd, J. C., R. K. Dodge, A. Carroll, M. R. Baer, C. Edwards, J. Stamberg, M. Qumsiyeh, et al. “Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.J Clin Oncol 17, no. 12 (December 1999): 3767–75. https://doi.org/10.1200/JCO.1999.17.12.3767.
Byrd, J. C., et al. “Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.J Clin Oncol, vol. 17, no. 12, Dec. 1999, pp. 3767–75. Pubmed, doi:10.1200/JCO.1999.17.12.3767.
Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec;17(12):3767–3775.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

December 1999

Volume

17

Issue

12

Start / End Page

3767 / 3775

Location

United States

Related Subject Headings

  • Translocation, Genetic
  • Survival Analysis
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Humans
  • Female
  • Drug Administration Schedule